We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+6.19%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$271M
AUM Growth
+$8.22M
Cap. Flow
+$4.83M
Cap. Flow %
1.78%
Top 10 Hldgs %
72.9%
Holding
39
New
14
Increased
6
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$13.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.36M
3
MRK icon
Merck
MRK
+$7.02M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$2.35M
5
AZN icon
AstraZeneca
AZN
+$1.65M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$26.1M
2
ARGX icon
argenx
ARGX
+$18.1M
3
NVO
Novo Nordisk
NVO
+$7.09M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$2.46M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 91.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
26
Roivant Sciences
ROIV
$25B
$1.16M 0.43%
+157,763
New +$1.3M
VKTX icon
27
Viking Therapeutics
VKTX
$3.84B
$1.14M 0.42%
68,408
-62,505
-48% -$646K
KYNB
28
Kyntra Bio
KYNB
$28M
$966K 0.36%
+2,072
New +$1.1M
WAT icon
29
Waters Corp
WAT
$38.9B
$881K 0.33%
2,845
– –
PCVX icon
30
Vaxcyte
PCVX
$7.9B
$853K 0.32%
+22,759
New +$965K
TYRA icon
31
Tyra Biosciences
TYRA
$1.93B
$727K 0.27%
+45,253
New +$538K
ALT icon
32
CALL
Altimmune
ALT
$597M
$422K 0.16%
+100,000
New +$1.19M
AMRN
33
Amarin Corp
AMRN
$302M
$385K 0.14%
+12,840
New +$450K
AMLX icon
34
Amylyx Pharmaceuticals
AMLX
$2.43B
$245K 0.09%
8,339
-15,544
-65% -$540K
LEGN icon
35
Legend Biotech
LEGN
$3.7B
$241K 0.09%
+5,000
New +$245K
LRMR icon
36
Larimar Therapeutics
LRMR
$427M
$172K 0.06%
+38,057
New +$199K
KYMR icon
37
Kymera Therapeutics
KYMR
$8.59B
– –
-30,000
Closed -$749K
MRNA icon
38
CALL
Moderna
MRNA
$22.8B
– –
-10,000
Closed -$1.8M
RXDX
39
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-22,321
Closed -$2.46M
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Artia Global Partners held 39 positions worth $271M, up 3.1% from $262M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Artia Global Partners's Q1 2023 filing shows 14 new, 6 increased, 7 reduced and 3 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 40,000 shares worth $3.64M. The largest sale was Eli Lilly, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier.

  • Artia Global Partners's largest Q1 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 40,000 shares worth $3.64M.
  • Artia Global Partners added most to Biogen in Q1 2023, an estimated $13.8M increase.
  • Artia Global Partners's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $26.1M.
  • Artia Global Partners fully exited Prometheus Biosciences, Inc. Common Stock in Q1 2023, selling an estimated $2.46M.
  • Artia Global Partners's ten largest holdings make up 73% of its $271M portfolio in Q1 2023.
  • Artia Global Partners opened 14 new positions and closed 3 in Q1 2023.
  • Artia Global Partners's portfolio value rose 3.1% quarter-over-quarter to $271M.

Based on Artia Global Partners's 13F filing for Q1 2023, filed 15 May 2023.